53 related articles for article (PubMed ID: 20164672)
1. [Monitoring of metastatic renal cell carcinoma--standards and challenges].
Jäger E
Onkologie; 2010; 33 Suppl 1():15-7. PubMed ID: 20164672
[TBL] [Abstract][Full Text] [Related]
2. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
Bergmann L
Onkologie; 2010; 33 Suppl 1():2-4. PubMed ID: 20164668
[TBL] [Abstract][Full Text] [Related]
3. [First-line therapy of metastatic renal cell carcinoma--update 2009].
Miller K
Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
[TBL] [Abstract][Full Text] [Related]
4. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
Marschner N
Onkologie; 2010; 33 Suppl 1():12-4. PubMed ID: 20164671
[TBL] [Abstract][Full Text] [Related]
5. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
6. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Gschwend JE
Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
[TBL] [Abstract][Full Text] [Related]
7. [Outlook: Future therapy of renal cell carcinoma].
Bergmann L; Miller K
Onkologie; 2010; 33 Suppl 1():18-20. PubMed ID: 20164673
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
Hutson TE
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
10. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
13. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
[TBL] [Abstract][Full Text] [Related]
14. Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
Valls L; Hoimes C; Sher A; Hu L; Lee Z; Muzic R; Avril N
Semin Roentgenol; 2014 Jul; 49(3):238-41. PubMed ID: 25497908
[No Abstract] [Full Text] [Related]
15. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
16. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
18. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
